2008-07-09 09:27:07 -

- Regulatory News:

Medivir (STO:MVIRB):

-- Consolidated net sales were SEK 14.7 (66.8) m in the period. In May, Medivir signed an agreement with Tibotec Pharmaceuticals Ltd. on hepatitis C, triggering a SEK 46.2 m (EUR 5.0 m) payment. This amount has been allocated over the assessed agreement term, with SEK 3.9 m recognized as revenue.

--

The loss after tax amounted to SEK -77.3 (-98.0) m.

-- Earnings per share were SEK -3.71 (-5.84).

-- Cash flow from operating activities was SEK 1.2 (-86.2) m.

-- Liquid assets as of 30 June were SEK 329.2 (313.1) m.

This information was brought to you by Cision newsroom.cision.com

Medivir
Rein Piir, CFO and VP, Investor Relations
+46 (0)8 546 83123 or +46 (0)70 853 7292